Is DRUG or EBS more undervalued in 2026?

CirclFi compares Bright Minds Biosciences Inc. (DRUG) and Emergent BioSolutions Inc. (EBS) using 13 institutional-grade valuation models. DRUG has a Quality of Company score of 4.4/10 while EBS scores 8.3/10.

Which is a better buy — DRUG or EBS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DRUG and EBS valuations compare?

DRUG at $88.07 and EBS at $9.12 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DRUG vs EBS Valuation Comparison 2026 — Intrinsic Value Analysis

DRUG

Pharmaceutical Preparations

Bright Minds Biosciences Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$88.07

Last close

Models

8/13

Active

EBS

Pharmaceutical Preparations

Emergent BioSolutions Inc.

Quality

8.3

out of 10

Value Trap

SAFE

Price

$9.12

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	DRUG Fair Value	DRUG Upside	EBS Fair Value	EBS Upside
Bayesian DCF	Intrinsic	$22.34	-74.6%	$27.60	+202.6%
Earnings Power Value	Intrinsic	—	—	$52.15	+471.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$79.08	-10.2%	$14.57	+59.7%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRUG vs EBS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRUG vs EBS — Which Stock Is More Undervalued?

EBS scores higher with a 8.3/10 quality rating vs DRUG's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bright Minds Biosciences Inc. (DRUG) and Emergent BioSolutions Inc. (EBS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRUG currently trades at $88.07 with a QOC of 4.4/10, while EBS trades at $9.12 with a QOC of 8.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).